Mast Energy Developments PLC Business Update

RNS Number : 0965M

Mast Energy Developments PLC

26 April 2024

 

Mast Energy Developments PLC

(Incorporated in England and Wales)

(Registration Number: 12886458)

LEI :213800HFVHGJ9YGO9F71

Share code on the LSE: MAST

ISIN: GB00BMBSCV12

('MED' or 'the Company')

 

Dated: 26 April 2024

 

Mast Energy Developments PLC ('MED' or 'the Company')

 

Business Update

 

Mast Energy Developments PLC, the UK-based multi-asset owner, developer and operator in the rapidly growing flexible power market, is pleased to announce an update regarding business operational matters.

 

Pyebridge

 

Further to the Company's previous RNS announcement dated 11 April 2024, MED has now received official confirmation that its Pyebridge 9MW flexible power generation asset ("Pyebridge") has passed its Satisfactory Performance Days ("SPD") requirements under its current existing T-1 Capacity Market contract (the "CM Contract"). This means that Pyebridge will retain the current CM Contract's associated annual gross profit margin income of c. £308,000 which is paid and received monthly in arrears.

 

In addition to the current CM Contract, as previously announced MED's Pyebridge site has secured further Capacity Market contracts to ensure minimum annual gross profit margin income totaling c. £817,000 until 2028. The Pyebridge site's Capacity Market contracts' gross profit margin income payments are in addition to its electricity generation trading revenue via its PPA with Statkraft.

 

Further, following the recent successful completion of the first phase of the Pyebridge work programme, the final preparations for the next larger second phase (the "2^nd Phase") are near complete, and implementation is expected shortly. The 2^nd Phase will be performed in separate consecutive tranches on each of the Pyebridge site's 3x gensets, and is expected to take around 6 to 8 weeks per genset. The completion of each of the three consecutive tranches of the 2^nd Phase will result in each of the 3x gensets operating and generating at its full expected availability, efficiency, revenue generation and profitability potential.

 

The MED management team is working closely with RiverFort regarding the implementation of the 2^nd Phase which will be funded under the new Funding Agreement (see RNS dated 28 February 2024 for further details). MED appreciates the ongoing support that RiverFort provides to the Company and Pyebridge.

 

Pieter Krügel, MED CEO, commented: "We are pleased that our Pyebridge asset has successfully passed its SPD requirements, resulting in the retention of its current CM Contract's associated annual gross profit margin income of c. £308,000. The next step in the process at Pyebridge is to kick off the 2^nd Phase of the work programme, which is expected shortly. We are looking forward to updating the market with progress in due course."

 

 

ENDS

 

This announcement contains inside information for the purposes of the UK version of the Market Abuse Regulation (EU No. 596/2014) as it forms part of United Kingdom domestic law by virtue of the European Union (Withdrawal) Act 2018 ('UK MAR'). Upon the publication of this announcement, this inside information is now considered to be in the public domain.

 

For further information please visit www.med.energy or contact:

Pieter Krügel	[e-mail]	Mast Energy Developments PLC	CEO
Jon Belliss	[phone]	Novum Securities	Corporate Broker

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

UPDBUGDSSGDDGSU